Valuation: Alector, Inc.

Market Cap 311M 279M 258M 234M 437M 29.57B 443M 3.09B 1.23B 15.5B 1.17B 1.14B 49.16B P/E 2026 *
-4.65x
P/E 2027 * -2.51x
Enterprise Value 49.33M 44.28M 40.88M 37.07M 69.29M 4.69B 70.14M 490M 195M 2.46B 185M 181M 7.79B EV / Sales 2026 *
0.75x
EV / Sales 2027 * 0.48x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day+14.75%
1 week+6.60%
Current month+13.51%
1 month+7.69%
3 months+39.07%
6 months-10.64%
Current year+34.62%
1 week 1.72
Extreme 1.72
2.12
1 month 1.72
Extreme 1.72
2.73
Current year 1.37
Extreme 1.37
2.76
1 year 1.09
Extreme 1.09
2.76
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
27
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
10/14/26 A Free

Controller/Auditor

138,990 0.1245%
10/14/26 A Free

Founder

1,196,250 1.0714%
10/14/26 A Free

Chief Financial Officer

234,567 0.2101%
Change 5-day change 1-year change 3-year change Capi.($)
+14.75%+6.60%+40.00%-59.06% 311M
-3.10%-4.19%+32.67%+59.47% 63.48B
+0.33%+0.33%+10.16%+78.07% 54.55B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 44.75B
-1.30%-4.80%+16.05%+114.76% 41.62B
+1.26%-5.26%+221.12%+900.64% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+1.11%+15.18%+60.27%+49.33% 26.7B
+3.45%-6.52%+25.63%-8.55% 23.36B
Average +1.51%-0.41%+45.17%+133.23% 38.07B
Weighted average by Cap. -0.31%-1.27%+42.92%+155.11%

Financials

2026 *2027 *
Net sales 66.15M 59.37M 54.82M 49.71M 92.91M 6.28B 94.05M 657M 261M 3.29B 248M 243M 10.44B 11.4M 10.23M 9.44M 8.56M 16.01M 1.08B 16.2M 113M 44.97M 567M 42.78M 41.87M 1.8B
Net income -51.03M -45.8M -42.29M -38.35M -71.68M -4.85B -72.56M -507M -201M -2.54B -192M -187M -8.06B -111M -99.46M -91.84M -83.28M -156M -10.53B -158M -1.1B -437M -5.52B -416M -407M -17.5B
Net Debt -262M -235M -217M -197M -368M -24.89B -373M -2.6B -1.03B -13.04B -983M -962M -41.37B -306M -274M -253M -230M -430M -29.05B -435M -3.04B -1.21B -15.23B -1.15B -1.12B -48.28B
Projected Income Statement - Annual - Alector, Inc.
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
27/10/26 $2.100 +14.75% 4,569,826
26/10/26 $1.830 0.00% 2,659,495
23/10/26 $1.830 0.00% 2,035,035
22/10/26 $1.830 -2.14% 1,480,205
21/10/26 $1.870 -5.08% 1,141,620
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Alector, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.100USD
Average target price
3.900USD
Spread / Average Target
+85.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alector, Inc.
  1. Stock Market
  2. Stocks
  3. ALEC Stock